Effect of Transcranial Alternating Current Stimulation on Ataxia Symptoms of Spinocerebellar Ataxia Type 3: A Randomized Clinical Trial

Author:

Shirui Gan1,Xia Liu2,Wei Lin1,Huating Zeng3,Liangliang Qiu1,Xiaoping Cheng1,Wanli Zhang4,Yanhua Lian1,Yingjuan Zhang1,Zhaodi Wang1,Xichen Wang1,Ruying Yuan1,Xuanyu Chen1,Zhixian Ye1,Yue Zhang4,Wang Duolao5,Jun Ni1,Wang Ning6ORCID,Fu Ying7,Chen Xin-Yuan8ORCID,Qikui Sun8,Shuna Huang8

Affiliation:

1. The First Affiliated Hospital of Fujian Medical University

2. The First Affiliated Hospital of Fujian Medical University;Yantai Affiliated Hospital Of Binzhou Medical University

3. JianOu Municipal Hospital of Fujian Province

4. College of Mechanical Engineering and Automation, Fuzhou University

5. Liverpool School of Tropical Medicine

6. Department of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

7. Department of Neurology and Institute of Neurology, The First Affiliated Hospital of Fujian Medical University

8. First Affiliated Hospital of Fujian Medical University

Abstract

Abstract

Currently, there are no treatments to alter the natural course of spinocerebellar ataxia type 3 (SCA3). Transcranial alternating current stimulation (tACS) have the sustainable potential to alleviate SCA3. Therefore, we conducted a randomized controlled trial enrolling 158 patients with SCA3 to investigate the safety and efficacy of tACS (NCT05557786). Enrolled participants received Active-tACS or Sham-tACS treatment 5 days/week for 2 weeks. The primary outcome was the proportion of participants whose Scale for the Assessment and Rating of Ataxia score improved by at least 1.5 points compared with baseline on assessments immediately after treatment and at 1-month and 3-month follow-up visits. The primary outcome assessed in the intention-to-treat population was met by 32 of 40 patients in the active-tACS group (80%) and 4 of 40 patients in the sham-tACS group (OR, 2.04[95% CI, 1.75 to 2.38; P < 0.001]). These promising findings motivate additional study to establish guidelines for tACS as a clinically recommended treatment for cerebellar diseases.

Publisher

Springer Science and Business Media LLC

Reference58 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3